BUSINESS● LOWSep 22 · Sep 22, 2026, 7:17 PM
Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg
Seeking Alpha Tech · north america
Nektar Therapeutics' stock has dropped as a jury deliberates in a patent dispute with Eli Lilly regarding their drug, Rezpeg. This event impacts the financial performance of a pharmaceutical company involved in litigation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS4m agoIn Kenya, the cancellation of the Vodafone-Safaricom deal threatens to weigh on the country's financesJeune AfriqueBUSINESS29m agoCLPS GAAP EPS of -$0.39, revenue of $87.1MSeeking Alpha Tech